GCET1 antibody
- Known as:
- GCET1 (anti-)
- Catalog number:
- orb100500
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- GCET1 antibody
Related genes to: GCET1 antibody
- Gene:
- SERPINA9 NIH gene
- Name:
- serpin family A member 9
- Previous symbol:
- -
- Synonyms:
- CENTERIN, SERPINA11b, GCET1
- Chromosome:
- 14q32.13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-27
- Date modifiied:
- 2016-10-05
Related products to: GCET1 antibody
Related articles to: GCET1 antibody
- Antiretroviral therapy (ART) is shifting the primary driver of mortality for people with HIV (PWH) from opportunistic infections to noncommunicable diseases (NCDs). Protein biomarkers differentiating both AIDS-related and NCDs-related deaths from PWH may help early and precise risk prediction and intervention. We conduct a nested case-control study where 126 HIV deaths, 162 age-sex-matched HIV survivors and 152 HIV-negative controls are analyzed with 92 protein biomarkers of the Olink Organ Damage panel by proximity extension assays (PEA). Using LASSO regression, logistic regression, and ROC analysis, twelve proteins are significantly associated with HIV death, of which six (SIRT5, PPM1B, PSMA1, GALNT10, VEGFC, PTN) are specifically associated with NCDs-related death, two (RCOR1, SERPINA9) are specifically associated with AIDS-related death, and four (CA12, CA14, RARRES1, EDIL3) are associated with both. Three of these proteins are replicable in the external validation sample. The adjusted protein panels consisting of significantly associated proteins selected through both LASSO and logistic regression model well predicted NCDs-related death (AUC = 0.970) and AIDS-related death (AUC = 0.960) in PWH. The selected proteins also displayed a significant correlation with traditional biomarkers of NCDs among PWH (P < 0.05). The potential clinical utility of these biomarkers could shed light on pathogenesis of end-stage organ dysfunction in PWH. - Source: PubMed
Publication date: 2025/04/24
Lin HaijiangHe JiayuRen JiyuanChen XiaoxiaoWang TingtingZhang HaijunWang ShanlingWang MiaochenChen TailinDuan SongHe Na - CAR T cell therapy provided transformative outcomes for patients with B-cell lymphoma; however, a large fraction of patients remains at risk for relapse, underlying the need to uncover mechanisms of resistance and predictive biomarkers. Herein, we leveraged the ZUMA-7 phase III randomized trial of relapsed/refractory large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (axi-cel; CD19-targeting CAR T cells) to discover tumor gene expression signatures (GES) associated with outcome. - Source: PubMed
Publication date: 2025/02/27
Tian YuanBudka JustinLocke Frederick LWestin Jason RTo ChristinaTiwari GayatriMao DaqinBedognetti DavideShen Rhine RAndrade JorgeFilosto Simone - Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is prevalent in the Asian population; however, little is known about its molecular characteristics. In this study, we examined the CD30 expression in ENKTLs and then performed whole exome sequencing on ten CD30 ENKTL and CD30 ENKTL paired samples. CD30 was positive in 55.74% of the ENKTLs. Single nucleotide and insertion/deletion polymorphism analyses revealed that 53.41% of the somatic mutations in CD30 ENKTLs were shared with CD30 ENKTLs, including mutations in SERPINA9, MEGF6, MUC6, and KDM5A. Frequently mutated genes were primarily associated with cell proliferation and migration, the tumor microenvironment, energy and metabolism, epigenetic modulators, vascular remodeling, and neurological function. PI3K-AKT, cAMP, cGMP-PKG, and AMPK pathways were enriched in both CD30 and CD30 ENKTLs. Copy number variation analysis identified a unique set of genes in CD30 ENKTLs, including T-cell receptor genes (TRBV6-1 and TRBV8), cell cycle-related genes (MYC and CCND3), immune-related genes (GPS2, IFNA14, TTC38, and CTSV), and a large number of ubiquitination-related genes (USP32, TRIM23, TRIM2, DUSP7, and UBE2QL1). BCL10 mutation was identified in 6/10 CD30 ENKTLs and 7/10 CD30 ENKTLs. Immunohistochemical analysis revealed that the expression pattern of BCL10 in normal lymphoid tissues was similar to that of BCL2; however, its expression in ENKTL cells was significantly higher (67.92% vs. 16.98%), implying the potential application of BCL10 inhibitors for treating ENKTLs. These results provide new insights into the genetic characteristics of CD30 and CD30 ENKTLs, and could facilitate the clinical development of novel therapies for ENKTL. - Source: PubMed
Publication date: 2024/08/24
Zhang XiaoyingLiang KeChen HaiyanLiu LongLiu RuiruiWang ChunxueZhang Cuijuan - Biological heterogeneity of large B cell lymphomas (LBCLs) is poorly captured by current prognostic tools, hampering optimal treatment decisions. - Source: PubMed
Publication date: 2024/04/04
Arffman MaareMeriranta LeoAutio MatiasHolte HaraldJørgensen JuditBrown PeterJyrkkiö SirkkuJerkeman MatsDrott KristinaFluge ØysteinBjörkholm MagnusKarjalainen-Lindsberg Marja-LiisaBeiske KlausPedersen Mette ØlgodLeivonen Suvi-KatriLeppä Sirpa - Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease that is classified into germinal center B-cell (GCB) and non-GCB subtypes, which are prognostically different. The Hans algorithm is the most widely used tool based on CD10, BCL6, and MUM1 expression, but some cases with the non-GCB phenotype are still known to be misclassified. In this study, we investigate the extent to which GCET1, HGAL, and LMO2 protein expressions reflect GCB phenotype together with their roles in determining the GCB phenotype of DLBCL and their contributions to the performance of the Hans algorithm. - Source: PubMed
Publication date: 2023/07/31
Berker NeslihanYeğen GülçinÖzlük YaseminDoğan Öner